Eloxx Pharmaceuticals (ELOX) Given Buy Rating at Canaccord Genuity

Share on StockTwits

Canaccord Genuity restated their buy rating on shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) in a research note published on Wednesday, The Fly reports. They currently have a $17.00 price objective on the stock, down from their previous price objective of $20.00. The analysts noted that the move was a valuation call.

Separately, Zacks Investment Research raised shares of Eloxx Pharmaceuticals from a hold rating to a buy rating and set a $13.00 target price for the company in a report on Monday, May 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $19.40.

OTCMKTS:ELOX opened at $10.66 on Wednesday. Eloxx Pharmaceuticals has a one year low of $9.12 and a one year high of $24.60.

Eloxx Pharmaceuticals (OTCMKTS:ELOX) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.08.

A number of institutional investors have recently modified their holdings of the business. Citigroup Inc. raised its holdings in Eloxx Pharmaceuticals by 20.6% in the fourth quarter. Citigroup Inc. now owns 7,432 shares of the company’s stock worth $89,000 after buying an additional 1,269 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Eloxx Pharmaceuticals by 6.0% in the fourth quarter. Bank of New York Mellon Corp now owns 67,111 shares of the company’s stock worth $806,000 after buying an additional 3,800 shares during the last quarter. BNP Paribas Arbitrage SA purchased a new position in Eloxx Pharmaceuticals in the first quarter worth about $55,000. Northern Trust Corp raised its holdings in Eloxx Pharmaceuticals by 2.0% in the first quarter. Northern Trust Corp now owns 287,081 shares of the company’s stock worth $3,353,000 after buying an additional 5,547 shares during the last quarter. Finally, Wells Fargo & Company MN raised its holdings in Eloxx Pharmaceuticals by 16.1% in the first quarter. Wells Fargo & Company MN now owns 42,302 shares of the company’s stock worth $494,000 after buying an additional 5,868 shares during the last quarter.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Featured Story: What are defining characteristics of a correction?

The Fly

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.